Compare Sana Biotechnology Inc (SANA) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard High Dividend Yield ETF — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $947.48M), while Vanguard High Dividend Yield ETF trades at $163. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VYM | |
|---|---|---|
Market Cap | $947.48M | — |
Sector | Health | — |
52-Week High | $5.92 | $167.03 |
52-Week Low | $2.68 | $137.47 |
Enterprise Value | $860.73M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
VYM trades at $163.52, down 0.43% on the day, with technical indicators showing a bearish bias amid neutral oscillators. The ETF's current price sits near key support at $163, with resistance at $164. Recent news highlights VYM's 16% YTD total return outperformance versus SPY, with analysts noting its attractive valuation at a forward P/E of 18.85x compared to SPY's 20-21x, offering a higher earnings yield and 2.20% dividend.
The outlook for VYM remains balanced with technical weakness offset by fundamental value. Investment opportunities include sector diversification with financials exposure benefiting from higher rates, while risks involve yield compression and market volatility. Analyst sentiment is mixed with recent upgrades citing valuation appeal, though technical trends suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
